190 related articles for article (PubMed ID: 35697931)
41. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
[TBL] [Abstract][Full Text] [Related]
42. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
43. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
Guerrini MM; Sobacchi C; Cassani B; Abinun M; Kilic SS; Pangrazio A; Moratto D; Mazzolari E; Clayton-Smith J; Orchard P; Coxon FP; Helfrich MH; Crockett JC; Mellis D; Vellodi A; Tezcan I; Notarangelo LD; Rogers MJ; Vezzoni P; Villa A; Frattini A
Am J Hum Genet; 2008 Jul; 83(1):64-76. PubMed ID: 18606301
[TBL] [Abstract][Full Text] [Related]
44. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract][Full Text] [Related]
45. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
[TBL] [Abstract][Full Text] [Related]
46. Case Report: A Case of Gallbladder Carcinosarcoma With Osteoclast-like Multinucleated Giant Cells that Was Associated With RANK-RANKL Signaling.
Niwa A; Tomita H; Watanabe N; Kiriyama S; Hara A; Tanaka T
Pathol Oncol Res; 2022; 28():1610134. PubMed ID: 35401056
[No Abstract] [Full Text] [Related]
47. Pleural malignant mesothelioma with osteoclast-like giant cells.
Itami H; Ohbayashi C; Sakai Y; Kajimoto K; Sakuma T
Pathol Int; 2010 Mar; 60(3):217-21. PubMed ID: 20403048
[TBL] [Abstract][Full Text] [Related]
48. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis.
Yang G; Yin J; Ou K; Du Q; Ren W; Jin Y; Peng L; Yang L
BMC Gastroenterol; 2020 Jun; 20(1):202. PubMed ID: 32590950
[TBL] [Abstract][Full Text] [Related]
49. A case of atypical gastric carcinoma with osteoclast like giant cells.
Pandit R; Danilova IA
Mcgill J Med; 2008 Jul; 11(2):152-5. PubMed ID: 19148314
[TBL] [Abstract][Full Text] [Related]
50. Metaplastic Carcinoma of the Breast: Analysis of 38 Cases from a Single Institute.
Hasbay B; Bolat FA; Aytaç HÖ; Aslan H; Purbager A
Turk Patoloji Derg; 2020; 36(1):23-30. PubMed ID: 31769499
[TBL] [Abstract][Full Text] [Related]
51. Special Histologic Type and Rare Breast Tumors - Diagnostic Review and Clinico-Pathological Implications.
Tan BY; Lim EH; Tan PH
Surg Pathol Clin; 2022 Mar; 15(1):29-55. PubMed ID: 35236633
[TBL] [Abstract][Full Text] [Related]
52. Osteoprotegerin influences the bone resorption activity of osteoclasts.
Fu YX; Gu JH; Zhang YR; Tong XS; Zhao HY; Yuan Y; Liu XZ; Bian JC; Liu ZP
Int J Mol Med; 2013 Jun; 31(6):1411-7. PubMed ID: 23563320
[TBL] [Abstract][Full Text] [Related]
53. [Leiomyosarcoma with prominent osteoclast-like giant cells: a clinicopathologic analysis of 7 cases and review of literature].
Li Y; Xu XL; Wang J
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):363-7. PubMed ID: 21914342
[TBL] [Abstract][Full Text] [Related]
54. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
55. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
56. Undifferentiated carcinoma with osteoclast-like giant cells of pancreas on cytology: A case report with review of literature.
Gupta K; Goyal S; Chaudhary D; Sakhuja P; Narang P; Nag HH
Diagn Cytopathol; 2022 Oct; 50(10):E289-E294. PubMed ID: 35678119
[TBL] [Abstract][Full Text] [Related]
57. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
[TBL] [Abstract][Full Text] [Related]
58. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
López-Bonet E; Alonso-Ruano M; Barraza G; Vazquez-Martin A; Bernadó L; Menendez JA
Oncol Rep; 2008 Dec; 20(6):1369-74. PubMed ID: 19020716
[TBL] [Abstract][Full Text] [Related]
59. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
Karst M; Gorny G; Galvin RJ; Oursler MJ
J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
[TBL] [Abstract][Full Text] [Related]
60. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
